Arbaclofen in fragile X syndrome: results of phase 3 trials
Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann W, Cherubini M, Zarevics P, Walton-Bowen K, Wang P, Bear M, Carpenter R. Arbaclofen in fragile X syndrome: results of phase 3 trials. Journal Of Neurodevelopmental Disorders 2017, 9: 3. PMID: 28616094, PMCID: PMC5467054, DOI: 10.1186/s11689-016-9181-6.Peer-Reviewed Original ResearchClinical Global Impression-ImprovementFragile X syndromeClinical Global Impression-SeveritySocial avoidanceABC-CFXAberrant Behavior Checklist-Community EditionHigh dose groupAnimal models of fragile X syndromeX syndromeModel of fragile X syndromeVineland Adaptive Behavior ScalesEffect sizeFlexible dose trialSerotonin reuptake inhibitorsSocial Avoidance subscaleChild studiesAdaptive Behavior ScalesAdolescent/adult studyFixed dose trialsDose groupParenting Stress IndexPhase 3 placebo-controlled trialsPreclinical models to clinical trialsResults of phase 3 trialsDose trial
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply